Intralesional low-dose methylprednisolone for the treatment of active phase Peyronie's disease: A single-centre, preliminary prospective non-randomised study.

Published in: International journal of clinical practice (2020)

In order to recover the symptoms and signs, new and easily accessible drugs are required for use in the acute period of Peyronie's disease. In this context, treatment with intralesional low-dose methylprednisolone in acute phase Peyronie's Disease is a promising and safe treatment option.

Keyphrases

low dose
high dose
clinical trial
randomized controlled trial
liver failure
depressive symptoms
open label
combination therapy
study protocol
intensive care unit
replacement therapy
acute respiratory distress syndrome